Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Ovarian Neoplasms 46Lung Neoplasms 26Breast Neoplasms 26Fallopian Tube Neoplasms 23Small Cell Lung Carcinoma 18Carcinoma, Ovarian Epithelial 16Squamous Cell Carcinoma of Head and Neck 14Neoplasms 14Glioblastoma 13Triple Negative Breast Neoplasms 12Recurrence 11Head and Neck Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Endometrial Neoplasms 10Uterine Cervical Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 8Hodgkin Disease 8Brain Neoplasms 8Lymphoma 7Esophageal Neoplasms 7Central Nervous System Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Glioma 6Esophageal Squamous Cell Carcinoma 6Astrocytoma 6Adenocarcinoma of Lung 6Mesothelioma 5

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unresectable Locally Advanced or Metastatic Solid Tumors × Carboplatin × Clear all
NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡